GELS
Gelteq·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GELS
Gelteq Limited
A company focusing on developing gel conveying solutions and related patented technologies for a variety of products
Level 19
644 Chapel Street
South Yarra VIC
3141
Australia
--
Gelteq Limited was incorporated on 15 October 2018 under the laws of the State of Victoria, Australia. They are a clinical and science-based company focused on prescription drugs, supplements, pet care and other products. The "white label" gel delivery solution is what they make, and other companies rename it their own. Their main product is edible gels, which they call gels, and their application in gel-based dosage forms. The current product suite includes multiple products located in five core verticals — pets, sports, pharmaceutical (pharmaceutical), over-the-counter (OTC) and nutritional — all of which utilize patent-pending multi-component dosage forms, as well as a wide range of applications and consumers they expect. Their current focus is to license the technology to companies to develop and create new products that they can manufacture and sell within their established and researched markets, while they continue to manufacture existing products under license (" white label ").
Company Financials
Revenue & Expenses
GELS has released its 2024 Q4 earnings report, with revenue of 23.68K, reflecting a YoY change of -52.72%, and net profit of -756.59K, showing a YoY change of -19.80%. The Sankey diagram below clearly presents GELS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
